Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Dow
Medtronic
US Department of Justice
Cerilliant
Colorcon
Moodys
Cipla
AstraZeneca
Citi

Generated: December 16, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR BETA CAROTENE

« Back to Dashboard

Clinical Trials for Beta Carotene

Trial ID Title Status Sponsor Phase Summary
NCT00000152 Randomized Trial of Beta-Carotene and Macular Degeneration Unknown status National Eye Institute (NEI) Phase 3 To determine whether 50 mg of beta-carotene taken every other day reduces the risk of developing age-related macular degeneration (AMD) among male U.S. physicians who were aged 40 to 84 in 1982. To investigate the possible relationship of AMD with other antioxidants, including selenium and vitamins A, C, and E. To identify potential risk factors for development of AMD. Possible risk factors include height, systemic hypertension, cardiovascular disease, blood cholesterol, cigarette smoking, iris and skin color, sunlight exposure, body mass index, diabetes, and alcohol intake.
NCT00000157 Randomized Trial of Aspirin and Cataracts in U.S. Physicians Terminated National Eye Institute (NEI) Phase 3 To determine whether 325 mg of aspirin taken on -alternate days reduces the risk of developing cataract among male U.S. physicians who were aged 40 to 84 in 1982. To identify potential risk factors for cataract development, such as age, blood pressure, blood cholesterol, height, diabetes, medication use, and history of previous eye trauma or surgery.
NCT00000161 Randomized Trials of Vitamin Supplements and Eye Disease Unknown status National Eye Institute (NEI) Phase 3 To determine whether vitamin E supplementation reduces the risk of cataract and age-related macular degeneration (AMD) in women. To determine whether vitamin C supplementation reduces the risk of cataract and AMD in women. To determine whether beta-carotene supplementation reduces the risk of cataract and AMD in women. To determine whether alternate day, low-dose aspirin reduces the risk of cataract and AMD in women. To identify potential risk factors for cataract and AMD including cigarette smoking, alcohol intake, blood pressure, blood cholesterol, cardiovascular disease, height, body mass index, and diabetes.
NCT00000500 Physicians' Health Study Completed National Heart, Lung, and Blood Institute (NHLBI) Phase 3 To assess the effect on cardiovascular mortality of alternate-day consumption of 325 milligrams of aspirin and, secondarily, the effect on cancer incidence of alternate-day consumption of 50 milligrams of beta-carotene.
NCT00000500 Physicians' Health Study Completed Brigham and Women's Hospital Phase 3 To assess the effect on cardiovascular mortality of alternate-day consumption of 325 milligrams of aspirin and, secondarily, the effect on cancer incidence of alternate-day consumption of 50 milligrams of beta-carotene.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Beta Carotene

Condition Name

Condition Name for Beta Carotene
Intervention Trials
Heart Diseases 4
Cardiovascular Diseases 4
Myocardial Ischemia 3
Cataract 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Beta Carotene
Intervention Trials
Cardiovascular Diseases 4
Cataract 4
Macular Degeneration 4
Heart Diseases 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Beta Carotene

Trials by Country

Trials by Country for Beta Carotene
Location Trials
United States 53
United Kingdom 2
Israel 2
Iran, Islamic Republic of 2
Germany 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Beta Carotene
Location Trials
Massachusetts 3
Maryland 3
Texas 3
New York 3
Florida 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Beta Carotene

Clinical Trial Phase

Clinical Trial Phase for Beta Carotene
Clinical Trial Phase Trials
Phase 4 3
Phase 3 14
Phase 2/Phase 3 3
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Beta Carotene
Clinical Trial Phase Trials
Completed 16
Recruiting 5
Unknown status 5
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Beta Carotene

Sponsor Name

Sponsor Name for Beta Carotene
Sponsor Trials
National Heart, Lung, and Blood Institute (NHLBI) 5
National Eye Institute (NEI) 5
Brigham and Women's Hospital 2
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Beta Carotene
Sponsor Trials
Other 38
NIH 15
Industry 7
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
US Department of Justice
Accenture
Citi
Covington
Cerilliant
Moodys
Baxter
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.